Endothelial Pannexin 1–TRPV4 channel signaling

lowers pulmonary arterial pressure

Panx1-TRPV4 signaling in pulmonary endothelium

¹Zdravka Daneva; ^{1,2}Matteo Ottolini; ¹Yen-Lin Chen; ¹Eliska Klimentova; ³Soham A. Shah; ⁴Richard D. Minshall; ⁵Cheikh I. Seye; ⁶Victor E. Laubach; ⁷Brant E. Isakson; ^{1,7}Swapnil K. Sonkusare

¹Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA, 22908, USA;

²Department of Pharmacology, University of Virginia, Charlottesville, VA, 22908, USA;

³Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, 22908, USA;

⁴Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL, USA; Department of Pharmacology, University of Illinois at Chicago, Chicago, IL, USA;

⁵Department of Biochemistry, University of Missouri-Columbia, Columbia, MO, USA;

⁶Department of Surgery, University of Virginia, Charlottesville, VA, 22908, USA;

⁷Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, 22908, USA

Correspondence should be addressed to:

Swapnil K. Sonkusare, Ph.D.
University of Virginia School of Medicine
P.O. Box 801394
Charlottesville, VA 22908
E-mail: sks2n@virginia.edu
Phone: 434-297-7401

Key Words: Pannexin 1, TRP channels, pulmonary artery, endothelium, purinergic signaling, caveolin 1.

Abstract.

Pannexin 1 (Pax1) is an ATP-efflux channel that controls endothelial function in the systemic circulation. However, the roles of endothelial Pax1 in resistance-sized pulmonary arteries (PAs) are unknown. Extracellular ATP dilates PAs through activation of endothelial TRPV4 (transient receptor potential vanilloid 4) ion channels. We hypothesized that endothelial Pax1–ATP–TRPV4 channel signaling promotes vasodilation and lowers pulmonary arterial pressure (PAP). Endothelial, but not smooth muscle, knockout of Pax1 or TRPV4 increased PA contractility and raised PAP. Pax1-effluxed extracellular ATP signaled through purinergic P2Y2 receptor (P2Y2R) to activate protein kinase C α (PKC α), which in turn activated endothelial TRPV4 channels. Finally, caveolin-1 provided a signaling scaffold for endothelial Pax1, P2Y2R, PKC α , and TRPV4 channels in PAs, promoting their spatial proximity and enabling signaling interactions. These results indicate that endothelial Pax1–P2Y2R–TRPV4 channel signaling, facilitated by caveolin-1, reduces PA contractility and lowers PAP.

Introduction

The pulmonary endothelium exerts a dilatory influence on small, resistance-sized pulmonary arteries (PAs) and thereby lowers pulmonary arterial pressure (PAP). However, endothelial signaling mechanisms that control PA contractility remain poorly understood. In this regard, pannexin 1 (Pannx1), which is expressed in the pulmonary endothelium and epithelium¹, has emerged as a crucial controller of endothelial function^{2, 3}. Pannx1, the most studied member of the pannexin family, forms a hexameric transmembrane channel at the cell membrane that allows efflux of ATP from the cytosol^{4, 5}. Previous studies have indicated that Pannx1_{EC} promotes endothelium-dependent dilation of systemic arteries^{6, 7}, and endothelial cell (EC) Pannx1 (Pannx1_{EC}) has been linked to inflammation in pulmonary capillaries⁸. Beyond this, however, the physiological roles of Pannx1_{EC} in the pulmonary vasculature are largely unknown.

Extracellular ATP (eATP) was recently shown to activate TRPV4 (transient receptor potential vanilloid 4) channels in the endothelium of small PAs⁹, establishing endothelial TRPV4 (TRPV4_{EC}) channels as potential signaling targets of Pannx1_{EC} in the pulmonary circulation. Ca²⁺ influx through TRPV4_{EC} channels is known to dilate small PAs through activation of endothelial nitric oxide synthase (eNOS)⁹. These observations suggest that Pannx1_{EC}-released eATP may act through TRPV4_{EC} channels to reduce PA contractility and lower PAP.

Purinergic receptor signaling is an essential regulator of pulmonary vascular function¹⁰⁻¹³. Previous studies in small PAs showed that eATP activates TRPV4_{EC} channels through P2 purinergic receptors, although the precise P2 receptor subtype was not identified⁹. Pulmonary endothelium expresses both P2Y and P2X receptor subtypes. Konduri et al. showed that eATP dilates PAs through P2Y2 receptor (P2Y2R) activation and subsequent endothelial NO release¹³. Recent evidence from systemic ECs and other cell types also supports P2Y2R-dependent

activation of TRPV4 channels by eATP^{14, 15}. These findings raise the possibility that the endothelial P2Y2 receptor (P2Y2R_{EC}) may be the signaling intermediate for Panx1_{EC}–TRPV4_{EC} channel communication in PAs.

The linkage between Panx1_{EC}-mediated eATP release and subsequent activation of P2Y2R_{EC}–TRPV4_{EC} signaling could depend on the spatial proximity of individual elements—Panx1_{EC}, P2Y2R_{EC}, and TRPV4_{EC}—a functionality possibly provided by a signaling scaffold. Caveolin-1 (Cav-1), a structural protein that interacts with and stabilizes other proteins in the pulmonary circulation¹⁶, co-localizes with Panx1, P2Y2R, and TRPV4 channels in multiple cell types¹⁷⁻¹⁹. Notably, global Cav-1^{-/-} mice show elevated PAP, and endothelial Cav-1 (Cav-1_{EC})-dependent signaling is impaired in pulmonary hypertension²⁰⁻²².

Here, we tested the hypothesis that Panx1_{EC}–P2Y2R_{EC}–TRPV4_{EC} channel signaling, supported by a signaling scaffold provided by Cav-1_{EC}, reduces PA contractility and PAP. Using inducible, EC-specific Panx1^{-/-}, TRPV4^{-/-}, P2Y2R^{-/-} and Cav-1_{EC}^{-/-} mice, we show that endothelial Panx1–P2Y2R–TRPV4 signaling reduces PA contractility and lowers PAP. Panx1_{EC}-generated eATP acts via P2Y2R_{EC} stimulation to activate protein kinase Cα (PKCα) and thereby increase TRPV4_{EC} channel activity. Panx1_{EC}, P2Y2R_{EC}, PKCα, and TRPV4_{EC} channels co-localize with Cav-1_{EC}, ensuring spatial proximity among the individual elements and supporting signaling interactions. Overall, these findings advance our understanding of endothelial mechanisms that control PAP and suggest the possibility of targeting these mechanisms to lower PAP in pulmonary vascular disorders.

Results

Endothelial, but not smooth muscle, *Panx1*–TRPV4 signaling lowers PA contractility.

To clearly define the physiological roles of *Panx1*_{EC} and TRPV4_{EC} channels, we utilized tamoxifen-inducible, EC-specific *Panx1*_{EC}^{-/-} and TRPV4_{EC}^{-/-} mice^{23, 24}. Tamoxifen-injected TRPV4^{fl/fl} Cre⁻ (TRPV4^{fl/fl}) or *Panx1*^{fl/fl} Cre⁻ (*Panx1*^{fl/fl}) mice were used as controls^{8, 23}. TRPV4_{EC}^{-/-} mice showed elevated right ventricular systolic pressure (RVSP), a commonly used *in vivo* indicator of PAP (Fig. 1A). In pressure myography experiments, ATP (1 μmol/L)-induced dilation was absent in PAs from TRPV4_{EC}^{-/-} mice (Fig. 1B), confirming that ATP dilates PAs through TRPV4_{EC} channels. RVSP was also elevated in *Panx1*_{EC}^{-/-} mice (Fig. 1C). The Fulton Index, a ratio of right ventricular (RV) weight to left ventricle plus septal (LV + S) weight, was not altered in TRPV4_{EC}^{-/-} or *Panx1*_{EC}^{-/-} mice compared with the respective control mice, suggesting a lack of right ventricular hypertrophy in these mice (Table 1). Importantly, baseline RVSP was not altered in inducible, SMC-specific TRPV4 (TRPV4_{SMC}^{-/-}) or *Panx1* (*Panx1*_{SMC}^{-/-}) knockout mice (Fig. 1A and C). Functional cardiac MRI studies indicated no alterations in cardiac function in TRPV4_{EC}^{-/-} or *Panx1*_{EC}^{-/-} mice compared with the respective control mice (Table 1), suggesting that the changes in RVSP were not due to altered cardiac function.

Localized, unitary Ca²⁺ influx signals through TRPV4_{EC} channels, termed *TRPV4*_{EC} *sparklets*²⁵, were recorded in *en face*, 4th-order PAs (~ 50 μm) loaded with Fluo-4. Baseline TRPV4_{EC} sparklet activity and activity induced by a low concentration (1 nmol/L) of the specific TRPV4 channel agonist, GSK1016790A (hereafter, GSK101), were significantly reduced in PAs from *Panx1*_{EC}^{-/-} mice compared with those from *Panx1*^{fl/fl} mice (Fig. 1D). Additionally, the number of TRPV4_{EC} sparklet sites per cell was decreased in PAs from *Panx1*_{EC}^{-/-} mice (Fig. 1E). At a

higher level of TRPV4 channel activation (30 nmol/L GSK101), sparklet activity per site and sparklet sites per cell were not different between $\text{Pax1}_{\text{EC}}^{-/-}$ and control ($\text{Pax1}^{\text{fl/fl}}$) mice (Fig. 1F). Further, outwards currents through TRPV4_{EC} channels, elicited by 10 nM GSK101, were also lower in $\text{Pax1}_{\text{EC}}^{-/-}$ than $\text{Pax1}^{\text{fl/fl}}$ mice (Fig. 1G, *left* and *center*). However, TRPV4_{EC} channel currents, elicited by 100 nM GSK101, were not different between $\text{Pax1}_{\text{EC}}^{-/-}$ and $\text{Pax1}^{\text{fl/fl}}$ mice (Fig. 1G, *right*). These data support the concept that the reduced TRPV4_{EC} channel activity in $\text{Pax1}_{\text{EC}}^{-/-}$ mice is due to impaired channel regulation rather than a decrease in the number of functional TRPV4_{EC} channels. Moreover, isolated, pressurized 4th-order PAs (Fig. 1H) from TRPV4_{EC}^{-/-} mice and $\text{Pax1}_{\text{EC}}^{-/-}$ mice exhibited a greater contractile response to the thromboxane A₂ receptor agonist U46619 (1–300 nmol/L; Fig. 1I). Together, these data provide the first evidence that Pax1_{EC} , via regulation of TRPV4_{EC} channel activity, lowers resting PAP.

Pax1_{EC} -generated eATP acts through purinergic P2Y2R_{EC} stimulation to activate TRPV4_{EC} channels.

Bioluminescence measurements confirmed lower baseline eATP levels in PAs from $\text{Pax1}_{\text{EC}}^{-/-}$ mice compared with PAs from $\text{Pax1}^{\text{fl/fl}}$ mice (Fig. 2A), supporting an essential role for Pax1_{EC} channels as an eATP-release mechanism in PAs. PAs from TRPV4_{EC}^{-/-} mice, however, exhibited unaltered basal eATP levels. eATP was recently identified as a novel endogenous activator of TRPV4_{EC} channels in the pulmonary circulation⁹. Therefore, we tested whether Pax1_{EC} activates TRPV4_{EC} channels via eATP release. Addition of the eATP-hydrolyzing enzyme apyrase (100 U/mL) reduced the activity of TRPV4_{EC} sparklets in PAs from control mice but not those from $\text{Pax1}_{\text{EC}}^{-/-}$ mice (Fig. 2B), confirming the role of Pax1_{EC} -mediated eATP in TRPV4_{EC} channel activation.

The pulmonary endothelium expresses both P2X and P2Y purinergic receptors²⁶⁻²⁹. The main P2Y receptor subtypes in the pulmonary endothelium are P2Y1R and P2Y2R^{13, 26, 29}. The selective P2Y1R inhibitor MRS2179 (MRS, 10 μ mol/L) did not alter eATP activation of TRPV4_{EC} sparklets (Fig. 2C). In contrast, the selective P2Y2R inhibitor AR-C 118925XX (AR-C; 10 μ mol/L) completely abrogated the effect of eATP on TRPV4_{EC} sparklets (Fig. 2C). eATP was also unable to activate TRPV4_{EC} sparklets in inducible, endothelium-specific P2Y2R^{-/-} (P2Y2R_{EC}^{-/-}) mice (Fig. 2C), providing further evidence that eATP activates TRPV4_{EC} channels in PAs specifically via P2Y2R_{EC} signaling. The general P2X1-5 receptor inhibitor, PPADS (10 μ mol/L), and P2X7 receptor inhibitor, JNJ-47965567 (JNJ, 1 μ mol/L), did not alter the effect of eATP on TRPV4_{EC} sparklets, ruling out a role for P2X1-5/7 receptors in eATP activation of TRPV4_{EC} channels in PAs (Fig. 2D). In ECs freshly isolated from PAs of C57BL6 mice, ATP (10 μ M) increased the outward currents through TRPV4 channels (Fig. 2E). Furthermore, the selective P2Y2R agonist, 2-thiouridine-5'-triphosphate (2-thio UTP; 0.5 μ mol/L) activated TRPV4_{EC} sparklets in PAs from P2Y2R^{fl/fl} mice but not in PAs from P2Y2R_{EC}^{-/-} mice (Fig. 2F).

Similar to TRPV4_{EC}^{-/-} and Panx1_{EC}^{-/-} mice, P2Y2R_{EC}^{-/-} mice also showed elevated RVSP and an unaltered Fulton Index (Fig. 2G). Taken together, these findings demonstrate that P2Y2R_{EC} is the signaling intermediate for Panx1_{EC}–TRPV4_{EC} interactions in PAs.

Cav-1_{EC} provides a scaffold for Panx1_{EC}–P2Y2R_{EC}–TRPV4_{EC} signaling.

Cav-1_{EC}, an essential structural protein in the pulmonary circulation^{21, 22, 30}, has been shown to co-localize with Panx1, P2Y2R, and TRPV4 channels in multiple cell types^{17-19, 31}. Therefore, we hypothesized that Cav-1_{EC} provides a signaling scaffold that supports and maintains the spatial

proximity among the individual elements in the $\text{Pax1}_{\text{EC}}\text{--P2Y2R}_{\text{EC}}\text{--TRPV4}_{\text{EC}}$ pathway. To clearly delineate the role of Cav-1_{EC} in Pax1_{EC} -dependent signaling, we utilized inducible, endothelium-specific Cav-1 -knockout mice ($\text{Cav-1}_{\text{EC}}^{-/-}$; Fig. 3A and B). The loss of Cav-1_{EC} resulted in elevated RVSP in the absence of right ventricular hypertrophy (Fig. 3C), indicating a crucial role of Cav-1_{EC} in maintaining a low resting PAP. Baseline TRPV4_{EC} sparklet activity and activity induced by a low level of GSK101 (1 nmol/L) were reduced in PAs from $\text{Cav-1}_{\text{EC}}^{-/-}$ mice (Fig. 3D). However, higher-level activation of TRPV4_{EC} channels (30 nmol/L GSK101) resulted in similar TRPV4_{EC} sparklet activity between groups, suggesting that the number of functional TRPV4_{EC} channels is unaltered in $\text{Cav-1}_{\text{EC}}^{-/-}$ mice (Fig. 3D). Importantly, eATP-induced activation of TRPV4_{EC} sparklets was absent in PAs from $\text{Cav-1}_{\text{EC}}^{-/-}$ mice (Fig. 3E). These results provided the first functional evidence that Cav-1_{EC} is required for $\text{eATP--P2Y2R}_{\text{EC}}\text{--TRPV4}_{\text{EC}}$ signaling in PAs. To provide additional evidence to support Cav-1_{EC} -dependent co-localization of $\text{Pax1}_{\text{EC}}\text{--P2Y2R}_{\text{EC}}\text{--TRPV4}_{\text{EC}}$ signaling elements in PAs, we performed *in situ* proximity ligation assays (PLA), which confirmed that Cav-1_{EC} exists within nanometer proximity of Pax1_{EC} , P2Y2R_{EC} , and TRPV4_{EC} channels in PAs (Fig. 3F).

Cav-1_{EC} anchoring of $\text{PKC}\alpha$ mediates P2Y2R_{EC} -dependent activation of TRPV4_{EC} channels in PAs.

P2Y2R is a Gq protein-coupled receptor that activates the phospholipase C (PLC)–diacylglycerol (DAG)–PKC signaling pathway. Notably, PKC is known to phosphorylate TRPV4 channels and potentiate its activity³². eATP, the DAG analog OAG (1 $\mu\text{mol/L}$), and the PKC activator phorbol myristate acetate (PMA; 10 nmol/L) stimulated TRPV4_{EC} sparklet activity in

small PAs (Fig. 4A–C). Inhibition of PLC with U73122 (3 μ mol/L) abolished eATP activation of TRPV4_{EC} sparklets, but not OAG- or PMA-induced activation of TRPV4_{EC} sparklets. Moreover, the PKC α/β inhibitor Gö-6976 (1 μ mol/L) prevented activation of TRPV4_{EC} sparklets by ATP, OAG and PMA (Fig. 4A–C), supporting the concept that eATP activation of P2Y2_{REC} stimulates TRPV4_{EC} channel activity via PLC–DAG–PKC signaling in PAs. TRPV4_{EC} channel activation by PLC–DAG–PKC signaling was further supported by increased activity of TRPV4_{EC} sparklets in PAs from Cdh5-opto α 1 adrenergic receptor (Cdh5-opto α 1AR) mouse, which expresses light-sensitive α 1AR in endothelial cells. When activated with light (~473 nm), Opto α 1AR generates the secondary messengers IP3 and diacylglycerol (DAG)³³. Light activation resulted in increased activity of TRPV4_{EC} sparklets (Fig. 4D), an effect that was abolished by the PKC α/β inhibitor Gö-6976 (1 μ M).

Since Cav-1 possesses a PKC-binding domain³⁴ and exists in nanometer proximity with TRPV4_{EC} channels and P2Y2_{REC}, we tested the hypothesis that Cav-1_{EC} anchoring of PKC mediates P2Y2_{REC}–TRPV4_{EC} channel interaction in PAs. PLA experiments confirmed that PKC also exists in nanometer proximity with Cav-1_{EC} in PAs (Fig. 5A). The PKC-dependence of Cav-1_{EC} activation of TRPV4_{EC} channels was confirmed by studies in HEK293 cells transfected with TRPV4 alone or TRPV4 channels plus Cav-1 (Fig. 5B), which showed that TRPV4 currents were increased in the presence of Cav-1. Further, the PKC α/β inhibitor Gö-6916 (1 μ mol/L) reduced TRPV4 channel currents in Cav-1/TRPV4–co-transfected cells to the level of that in cells transfected with TRPV4 alone (Fig. 5B and C). These results imply that Cav-1 enhances TRPV4 channel activity via PKC α/β anchoring. Experiments in which TRPV4 channels were co-expressed with PKC α or PKC β showed that only PKC α increased currents through TRPV4 channels (Fig. 5D). Collectively, these results support the conclusion that Panx1_{EC}–P2Y2_{REC}–

PKC α –TRPV4_{EC} signaling on a Cav-1_{EC} scaffold reduces PA contractility and lowers resting PAP (Fig. 5E).

Discussion

Regulation of PA contractility and PAP is a complex process involving multiple cell types and signaling elements. In particular, the endothelial signaling mechanisms that control resting PAP remain poorly understood. Our studies identify a Panx1_{EC} and TRPV4_{EC} channel-containing signaling nanodomain that reduces PA contractility and lowers PAP. Although both Panx1_{EC} and TRPV4_{EC} channels have been implicated in dilation of systemic arteries, their impact on PAP remains unknown. We demonstrate critical roles for several key, linked mechanistic, pathways showing that 1) Panx1_{EC} increases eATP levels in small PAs; 2) Panx1_{EC}-generated eATP, in turn, enhances Ca²⁺ influx through TRPV4_{EC} channels, thereby dilating PAs and lowering PAP; 3) eATP acts through purinergic P2Y2_{REC}–PKC α signaling to activate TRPV4_{EC} channels; and 4) Cav-1_{EC} provides a signaling scaffold that ensures spatial proximity among the elements of the Panx1_{EC}–P2Y2_{REC}–PKC α –TRPV4_{EC} pathway. Our findings reveal a novel signaling axis that can be engaged by physiological stimuli to lower PAP and could also be therapeutically targeted in pulmonary vascular disorders. Moreover, the conclusions in this study may assist in future investigations of the mechanisms underlying pulmonary endothelial dysfunction.

Both ECs and SMCs control vascular contractility and arterial pressure. The expression of Panx1 and TRPV4 channels in both ECs and SMCs^{8, 18, 35-37} makes it challenging to decipher the cell type-specific roles of Panx1 and TRPV4 channels using global knockouts or pharmacological strategies. Therefore, studies utilizing EC- or SMC-specific knockout mice are necessary for a

definitive assessment of the control of PAP by EC and SMC Panx1 and TRPV4 channels. Although SMC TRPV4 channels have been shown to contribute to hypoxia-induced pulmonary vasoconstriction, resting PAP is not altered in global TRPV4^{-/-} mice^{38, 39}. Further, our studies indicate that SMC Panx1 and TRPV4 channels do not influence resting PAP. Taken together with findings from EC-knockout mice, these results provide strong evidence that endothelial, but not SMC, Panx1 and TRPV4 channels maintain low PA contractility and PAP under basal conditions.

Recent studies in pulmonary fibroblasts and other cell types suggest that TRPV4 channel-mediated increases in cytosolic Ca²⁺ can induce eATP release through Panx1^{40, 41}. However, the reverse interaction, in which Panx1-mediated eATP release activates TRPV4 channels, has not been explored in any cell type. Since Panx1 is activated by cytosolic Ca²⁺⁴² and eATP has been previously shown to activate TRPV4_{EC} channels⁹, bidirectional signaling between Panx1 and TRPV4 channels is conceivable. However, our demonstration that baseline eATP levels are unchanged in PAs from TRPV4_{EC}^{-/-} mice rules out a role for TRPV4_{EC} channels in controlling eATP release under baseline conditions. Nevertheless, these data from pulmonary ECs do not rule out potential TRPV4–Ca²⁺–Panx1 signaling in other cell types.

Elevated capillary TRPV4_{EC} channel activity has been linked to increased endothelial permeability^{43, 44}, lung injury⁴⁵, and pulmonary edema^{43, 44}. Moreover, Panx1_{EC}-mediated eATP release is associated with vascular inflammation at the level of capillaries⁸. The physiological roles of Panx1_{EC} and TRPV4_{EC} channels in PAs, however, remain unknown. ECs from pulmonary capillaries and arteries are structurally and functionally different. Whereas PAs control pulmonary vascular resistance and PAP, capillaries control vascular permeability. TRPV4_{EC} channels couple with distinct targets in arterial and capillary ECs^{25, 46}. Our data identify physiological roles of

Panx1_{EC}–TRPV4_{EC} channel signaling in PAs, but whether such signaling operates in the capillary endothelium and is essential for its physiological function is unclear.

Purinergic signaling and the endogenous purinergic receptor agonist eATP are essential controllers of pulmonary vascular function^{13, 26, 28, 47}. Our discovery of the Panx1_{EC}–P2Y2_{REC}–TRPV4_{EC} pathway establishes a signaling axis in ECs that regulates pulmonary vascular function. The pulmonary vasculature is a high-flow circulation, and pulmonary ECs have been shown to release eATP in response to flow/shear stress¹². Therefore, flow/shear stress could be a potential physiological activator of Panx1_{EC}–P2Y2_{REC}–TRPV4_{EC} signaling in PAs. Further studies are needed to verify this possibility. Several purinergic receptor subtypes are expressed in the pulmonary vasculature, including P2YRs and P2XRs²⁶⁻²⁸. Although only P2Y2_{REC} appears to mediate eATP activation of TRPV4_{EC} channels, our studies do not rule out potentially important roles for other P2Y or P2X receptors in the pulmonary endothelium.

Activation of TRPV4_{EC} channels by eATP released through Panx1_{EC} in PAs would be facilitated by spatial localization of TRPV4_{EC} channels with Panx1_{EC}. In keeping with this, several scaffolding proteins are known to promote localization of TRPV4 channels with their regulatory proteins, including A-kinase anchoring protein 150 (AKAP150) and Cav-1^{23, 48}. Although AKAP150 is not found in the pulmonary endothelium⁹, Cav-1 is a key structural protein in the pulmonary vasculature and has a well-established role in controlling pulmonary vascular function, as demonstrated by increased RVSP in global Cav-1^{-/-} mice^{49, 50}. Moreover, Cav-1–dependent signaling is impaired in pulmonary hypertension²⁰⁻²². Studies in other cell types have shown that Cav-1 can co-localize with Panx1 and P2Y2Rs^{18, 19}. Additionally, Cav-1 can interact with PKC at the Cav-1 scaffolding domain³⁴. Our results demonstrate that Cav-1_{EC} exists in nanometer proximity with Panx1_{EC}, P2Y2_{REC}, PKC, and TRPV4_{EC} channels in PAs. Furthermore, the

activation of TRPV_{4EC} channels by Panx1_{EC}, eATP, P2Y2R_{EC} or PKC α requires Cav-1_{EC}. Based on these findings, we conclude that Cav-1_{EC} enables Panx1_{EC}–P2Y2R_{EC}–TRPV_{4EC} signaling at EC membranes in PAs. Cav-1 is also a well-known anchor protein for eNOS¹⁶, acting by stabilizing eNOS expression and negatively regulating its activity¹⁶. We previously showed that TRPV_{4EC} Ca²⁺ sparklets activate eNOS in PAs^{9, 36}. Thus, Cav-1_{EC} enhancement of Ca²⁺ influx through TRPV_{4EC} channels may represent novel mechanisms for regulating eNOS activity.

Cav-1_{EC}/PKC α -dependent signaling is a novel endogenous mechanism for activating arterial TRPV_{4EC} channels and lowering PAP. Proximity to PKC α appears to be crucial for the normal function of TRPV4 channels. Evidence from the systemic circulation suggests that co-localization of TRPV4 channels with scaffolding proteins enhances their activity^{51, 52}, and we specifically demonstrated that PKC anchoring by AKAP150 enhances the activity of TRPV_{4EC} channels in mesenteric arteries²³. Here, we show that PKC anchoring by Cav-1_{EC} enables PKC activation of TRPV_{4EC} channels in PAs. This discovery raises the possibility that disruption of PKC anchoring by Cav-1_{EC} could impair the Panx1_{EC}–P2Y2R_{EC}–TRPV_{4EC} signaling axis under disease conditions. A lack of PKC anchoring by scaffolding proteins in systemic arteries has been demonstrated in obesity and hypertension^{23, 52}. Further studies of pulmonary vascular disorders are required to establish whether the Panx1_{EC}–P2Y2R_{EC}–PKC α –TRPV_{4EC} signaling axis is impaired in pulmonary vascular disorders.

In conclusion, Panx1_{EC}–TRPV_{4EC} signaling reduces PA contractility and maintains a low resting PAP. This mechanism is facilitated by eATP released through Panx1_{EC} and subsequent activation of P2Y2R_{EC}–PKC α signaling. Cav-1_{EC} ensures the spatial proximity among Panx1_{EC}, P2Y2R_{EC}, and TRPV_{4EC} channels and also anchors PKC α close to TRPV_{4EC} channels. These findings identify a novel endothelial Ca²⁺ signaling mechanism that reduces PA contractility.

Further investigations are needed to determine whether impairment of this pathway contributes to elevated PAP in pulmonary vascular disorders and whether this pathway can be targeted for therapeutic benefit.

Materials and Methods

Drugs and chemical compounds.

Cyclopiazonic acid (CPA), GSK2193874, GSK1016790A, Phorbol 12-myristate 13-acetate (PMA), AR-C 118925XX, 2-Thio UTP tetrasodium salt, MRS2179, U-73122 and NS309 were purchased from Tocris Bioscience (Minneapolis, MN, USA). Fluo-4-AM (Ca²⁺ indicator) were purchased from Invitrogen (Carlsbad, CA, USA). 1-O-9Z-octadecenoyl-2-O-acetyl-*sn*-glycerol (OAG), PPADS (sodium salt), Gö-6976, JNJ-47965567 and U46619 were purchased from Cayman Chemicals (Ann Arbor, MI, USA). Tamoxifen and apyrase were obtained from Sigma-Aldrich (St. Louis, MO, USA).

Animal protocols and models.

All animal protocols were approved by the University of Virginia Animal Care and Use Committee (protocols 4100 and 4120). This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. For surgical procedures, every effort was made to minimize suffering. Both male and female mice were used in this study and age- and sex-matched controls were used. C57BL6/J were obtained from the Jackson Laboratory (Bar Harbor, ME). Inducible endothelial

cell (EC)-specific TRPV4 channel knockout (TRPV4^{EC-/-})^{53, 54}, smooth muscle cell (SMC)-specific TRPV4 channel knockout (TRPV4^{SMC-/-})⁵⁵, EC caveolin-1 knockout (Cav-1^{EC-/-})⁵⁶, EC-specific P2Y2R receptor knockout (P2Y2R^{EC-/-})⁵⁷, EC-specific Panx1 channel knockout (Panx1^{EC-/-})^{24, 54} and SMC-specific Panx1 channel knockout (Panx1^{SMC-/-})⁵⁵ mice (10-14 weeks old) were used. The mouse strain Cdh5-optoα1AR was developed by CHROMusTM which is supported by the National Heart Lung Blood Institute of the National Institute of Health under award number R24HL120847. Mice were housed in an enriched environment and maintained under a 12:12 h light/dark photocycle at ~23°C with fresh tap water and standard chow diet available *ad libitum*. Mice were euthanized with pentobarbital (90 mg/kg⁻¹; intraperitoneally; Diamondback Drugs, Scottsdale, AZ) followed by cervical dislocation for harvesting lung tissue. Fourth-order pulmonary arteries (PAs, ~50 μm diameter) were isolated in cold HEPES-buffered physiological salt solution (HEPES-PSS, in mmol/L, 10 HEPES, 134 NaCl, 6 KCl, 1 MgCl₂ hexahydrate, 2 CaCl₂ dihydrate, and 7 dextrose, pH adjusted to 7.4 using 1 mol/L NaOH).

TRPV4^{fl/fl}⁵³, Cav-1^{fl/fl}⁵⁶, Panx1^{fl/fl}^{24, 54} and P2Y2R^{fl/fl}⁵⁷ mice were crossed with VE-Cadherin (Cdh5, endothelial) Cre mice⁵³ or SMMHC (smooth muscle) Cre mice⁵⁸. EC- or SMC-specific knockout of TRPV4, Cav-1, Panx1, or P2Y2R was induced by injecting 6 week-old TRPV4^{fl/fl} Cre⁺, Cav-1^{fl/fl} Cre⁺, Panx1^{fl/fl} Cre⁺ and P2Y2R^{fl/fl} Cre⁺ mice with tamoxifen (40 mg/kg intraperitoneally per day for 10 days). Tamoxifen-injected TRPV4^{fl/fl} Cre⁻, Cav-1^{fl/fl} Cre⁻, Panx1^{fl/fl} Cre⁻ and P2Y2R^{fl/fl} Cre⁻ mice were used as controls. Mice were used for experiments after a two-week washout period. Genotypes for Cdh5 Cre and SMMHC Cre were confirmed following previously published protocols^{53, 58}. TRPV4^{fl/fl}⁵³, Cav-1^{fl/fl}⁵⁶, Panx1^{fl/fl}^{24, 54}, P2Y2R^{fl/fl}⁵⁷ genotyping was performed as described previously. Cdh5-Optoα1AR mice were developed by CHROMus (Cornell University, USA).

Right ventricular systolic pressure (RVSP) and Fulton Index measurement.

Mice were anesthetized with pentobarbital (50 mg/kg bodyweight; intraperitoneally) and bupivacaine HCl (100 µL of 0.25% solution; subcutaneously) was used to numb the dissection site on the mouse. RVSP was measured as an indirect indicator of pulmonary arterial pressure (PAP). A Mikro-Tip pressure catheter (SPR-671; Millar Instruments, Huston, TX), connected to a bridge amp (FE221), and a PowerLab 4/35 4-channel recorder (Instruments, Colorado Springs, CO), was cannulated through the external jugular vein into the right ventricle. Right ventricular pressure and heart rate were acquired and analyzed using LabChart8 software (ADInstruments, Colorado Springs, CO). A stable 3-minute recording was acquired for all the animals, and 1-minute continuous segment was used for data analysis. When necessary, traces were digitally filtered using a low-pass filter at a cut-off frequency of 50 Hz. At the end of the experiments, mice were euthanized, and the hearts were isolated for right ventricular hypertrophy analysis. Right ventricular hypertrophy was determined by calculating the Fulton Index, a ratio of the right ventricular (RV) heart weight over the left ventricular (LV) plus septum (S) weight (RV/ LV+S).

Luciferase assay for total ATP release.

ATP assay protocol was adapted from Yang et al.⁵⁹. Fourth-order pulmonary arteries (PAs, ~ 50 µm diameter) were isolated in cold HEPES-buffered physiological salt solution (HEPES-PSS, in mmol/L, 10 HEPES, 134 NaCl, 6 KCl, 1 MgCl₂ hexahydrate, 2 CaCl₂ dihydrate, and 7 dextrose, pH adjusted to 7.4 using 1 mol/L NaOH). Isolated PAs were pinned down *en face* on a Sylgard block and cut open. PAs were placed in black, opaque 96-well

plates and incubated in HEPES-PSS for 10 minutes at 37 °C, followed by incubation with the ectonucleotidase inhibitor ARL 67156 (300 µmol/L, Tocris Bioscience, Minneapolis, MN) for 30 minutes at 37 °C. 50 µL volume of each sample was transferred to another black, opaque 96-well plate. ATP was measured using ATP bioluminescence assay reagent ATP Bioluminescence HSII kit (Roche Applied Science, Penzberg, Germany). Using a luminometer (FluoStar Omega), 50 µL of luciferin: luciferase reagent (ATP bioluminescence assay kit HSII; Roche Applied Science, Penzberg, Germany) was injected into each well and luminescence was recorded following a 5 second orbital mix and sample measurement at 7 seconds. ATP concentration in each sample was calculated from an ATP standard curve.

Cardiac Magnetic Resonance Imaging (MRI).

MRI studies were conducted under protocols that comply with the Guide for the Care and Use of Laboratory Animals (NIH publication no. 85-23, Revised 1996). Mice were positioned in the scanner under 1.25% isoflurane anesthesia and body temperature was maintained at 37°C using thermostatic circulating water. A cylindrical birdcage RF coil (30 mm-diameter, Bruker, Ettlingen, Germany) with an active length of 70 mm was used, and heart rate, respiration, and temperature were monitored during imaging using a fiber optic, MR-compatible system (Small Animal Imaging Inc., Stony Brook, NY). MRI was performed on a 7 Tesla (T) Clinscan system (Bruker, Ettlingen, Germany) equipped with actively shielded gradients with a full strength of 650 mT/m and a slew rate of 6666 mT/m/ms⁶⁰. Six short-axis slices were acquired from base to apex, with slice thickness of 1 mm, in-plane spatial resolution of $0.2 \times 0.2 \text{ mm}^2$, and temporal resolution of 8–12 ms. Baseline ejection fraction (EF), end-diastolic volume (EDV), end-systolic volume

(ESV), myocardial mass, wall thickness, stroke volume (SV), and cardiac output (CO) were assessed from the cine images using the freely available software Segment version 2.0 R5292 (<http://segment.heiberg.se>).

Pressure myography.

Isolated mouse PAs (~ 50 µm) were cannulated on glass micropipettes in a pressure myography chamber (The Instrumentation and Model Facility, University of Vermont, Burlington, VT) at areas lacking branching points, and were pressurized at a physiological pressure of 15 mm Hg³⁶. Arteries were superfused with PSS (in mmol/L, 119 NaCl, 4.7 KCl, 1.2 KH₂PO₄, 1.2 MgCl₂ hexahydrate, 2.5 CaCl₂ dihydrate, 7 dextrose, and 24 NaHCO₃) at 37°C and bubbled with 20% O₂/5% CO₂ to maintain the pH at 7.4. All drug treatments were added to the superfusing PSS. PAs were pre-constricted with 50 nmol/L U46619 (a thromboxane A₂ receptor agonist). All other pharmacological treatments were performed in the presence of U46619. Before measurement of vascular reactivity, arteries were treated with NS309 (1 µmol/L), a direct opener of endothelial IK/SK channels, to assess endothelial health. Arteries that failed to fully dilate to NS309 were discarded. Changes in arterial diameter were recorded at a 60-ms frame rate using a charge-coupled device camera and edge-detection software (IonOptix LLC, Westwood, MA)^{25, 52}. All drug treatments were incubated for 10 minutes. At the end of each experiment, Ca²⁺-free PSS (in mmol/L, 119 NaCl, 4.7 KCl, 1.2 KH₂PO₄, 1.2 MgCl₂ hexahydrate, 7 dextrose, 24 NaHCO₃, and 5 EGTA) was applied to assess the maximum passive diameter. Percent constriction was calculated by:

$$[(\text{Diameter}_{\text{before}} - \text{Diameter}_{\text{after}}) / \text{Diameter}_{\text{before}}] \times 100 \quad (1)$$

where $\text{Diameter}_{\text{before}}$ is the diameter of the artery before a treatment and $\text{Diameter}_{\text{after}}$ is the diameter after the treatment. Percent dilation was calculated by:

$$[(\text{Diameter}_{\text{dilated}} - \text{Diameter}_{\text{basal}}) / (\text{Diameter}_{\text{Ca-free}} - \text{Diameter}_{\text{basal}})] \times 100 \quad (2)$$

where $\text{Diameter}_{\text{basal}}$ is the stable diameter before drug treatment, $\text{Diameter}_{\text{dilated}}$ is the diameter after drug treatment, and $\text{Diameter}_{\text{Ca-free}}$ is the maximum passive diameter.

Ca²⁺ imaging.

Measurements of TRPV4_{EC} Ca²⁺ sparklets in the native endothelium of mouse PAs were performed as previously described²⁵. Briefly, 4th-order (~ 50 μm) PAs were pinned down *en face* on a Sylgard block and loaded with fluo-4-AM (10 μmol/L) in the presence of pluronic acid (0.04%) at 30°C for 30 minutes. TRPV4_{EC} Ca²⁺ sparklets were recorded at 30 frames per second with Andor Revolution WD (with Borealis) spinning-disk confocal imaging system (Oxford Instruments, Abingdon, UK) comprised of an upright Nikon microscope with a 60X water dipping objective (numerical aperture 1.0) and an electron multiplying charge coupled device camera (iXon 888, Oxford Instruments, Abingdon, UK). All experiments were carried out in the presence of cyclopiazonic acid (20 μmol/L, a sarco-endoplasmic reticulum (ER) Ca²⁺-ATPase inhibitor)

in order to eliminate the interference from Ca^{2+} release from intracellular stores. Fluo-4 was excited at 488 nm with a solid-state laser and emitted fluorescence was captured using a 525/36-nm band-pass filter. TRPV4_{EC} Ca^{2+} sparklets were recorded before and 5 minutes after the addition of specific compounds. To generate fractional fluorescence (F/F_0) traces, a region of interest defined by a $1.7\text{-}\mu\text{m}^2$ (5×5 pixels) box was placed at a point corresponding to peak sparklet amplitude. Each field of view was $\sim 110\times 110\text{ }\mu\text{m}$ and covered ~ 15 ECs. Representative F/F_0 traces were filtered using a Gaussian filter and a cutoff corner frequency of 4 Hz. Sparklet activity was assessed as described previously using the custom-designed SparkAn software^{25, 52}.

For the experiments in Cdh5-opto1AR mice, PAs were loaded with X-Rhod-1 AM ($5\text{ }\mu\text{M}$, Thermo Fisher Scientific Inc., Waltham, MA, USA) for 30 minutes at 30°C . X-Rhod-1 was excited at 561 nm and the emitted light was captured with a 607/36-nm band-pass filter. Opto1AR was activated at 470 nm for 5 seconds using pE-4000 (CoolLED Ltd, Andover, UK).

Calculation of TRPV4 sparklet activity per site.

Activity of TRPV4 Ca^{2+} sparklets was evaluated as described previously^{25, 52}. Area under the curve for all the events at a site was determined using trapezoidal numerical integration ($[F-F_0]/F_0$ over time, in seconds). The average number of active TRPV4 channels, as defined by NP_0 (where N is the number of channels at a site and P_0 is the open state probability of the channel), was calculated by

$$\text{NP}_0 = (\text{T}_{\text{level1}} + 2\text{T}_{\text{level2}} + 3\text{T}_{\text{level3}} + 4\text{T}_{\text{level4}}) / \text{T}_{\text{total}} \quad (3)$$

453

454 where T is the dwell time at each quantal level detected at TRPV4 sparklet sites and T_{total} is the
455 duration of the recording. NP_O was determined using Single Channel Search module of Clampfit
456 and quantal amplitudes derived from all-points histograms⁹ ($\Delta F/F_0$ of 0.29 for Fluo-4 –loaded
457 PAs).

458 Total number of sparklet sites in a field was divided by the number of cells in that field to obtain
459 sparklet sites per cell.

460

461 **Immunostaining.**

462 Immunostaining was performed on 4th-order PAs (~ 50 μm) pinned *en face* on SYLGARD
463 blocks. PAs were fixed with 4% paraformaldehyde (PFA) at room temperature for 15 minutes and
464 then washed 3 times with phosphate-buffered saline (PBS). The tissue was permeabilized with
465 0.2% Triton-X for 30 minutes, blocked with 5% normal donkey serum (ab7475, Abcam,
466 Cambridge, MA) or normal goat serum (ab7475, Abcam, Cambridge, MA), depending on the host
467 of the secondary antibody used, for 1 hour at room temperature. PAs were incubated with the
468 primary antibodies (Table 2) overnight at 4°C. Following the overnight incubation, PAs were
469 incubated with secondary antibody 1:500 Alexa Fluor® 568-conjugated donkey anti-rabbit (Life
470 Technologies, Carlsbad, CA, USA) for one hour at room temperature in the dark room. For nuclear
471 staining, PAs were washed with PBS and then incubated with 0.3 mmol/L DAPI (Invitrogen,
472 Carlsbad, CA, USA) for 10 minutes at room temperature. Images were acquired along the z-axis
473 from the surface of the endothelium to the bottom where the EC layer encounters the smooth
474 muscle cell layer with a slice size of 0.1 μm using the Andor microscope described above. The

internal elastic lamina (IEL) autofluorescence was evaluated using an excitation of 488 nm with a solid-state laser and collecting the emitted fluorescence with a 525/36 nm band-pass filter. Immunostaining for the protein of interest was evaluated using an excitation of 561 nm and collecting the emitted fluorescence with a 607/36 nm band-pass filter. DAPI immunostaining was evaluated using an excitation of 409 nm and collecting the emitted fluorescence with a 447/69 nm band-pass filter.

***In situ* Proximity Ligation Assay (PLA).**

Fourth-order (~ 50 µm) PAs were pinned *en face* on SYLGARD blocks. PAs were fixed with 4% PFA for 15 minutes followed by three washes with PBS. PAs were then permeabilized with 0.2% Triton X for 30 minutes at room temperature followed by blocking with 5% normal donkey serum (Abcam plc, Cambridge, MA, USA) and 300 mmol/L glycine for one hour at room temperature. After three washes with PBS, PAs were incubated with the primary antibodies (Table 2) overnight at 4 °C. The PLA protocol from Duolink PLA Technology kit (Sigma-Aldrich, St. Louis, MO, USA) was followed for the detection of co-localized proteins. Lastly, PAs were incubated with 0.3 mmol/L DAPI nuclear staining (Invitrogen, Carlsbad, CA, USA) for 10 minutes at room temperature in the dark room. PLA images were acquired using the Andor Revolution spinning-disk confocal imaging system along the z-axis at a slice size of 0.1 µm. Images were analyzed by normalizing the number of positive puncta by the number of nuclei in a field of view.

Table 2. List of antibodies used for immunostaining and PLA on *en face* PAs.

Protein	Product no.	Company	Clonality	Concentration
TRPV4	LSC 94498	LifeSpan BioScience INC	Polyclonal	1:200
Cav-1	Ab2910	Abcam plc.	Polyclonal	1:500
Cav-1 (PLA only)	NB100-615	Novus Biologicals, LLC	Monoclonal	1:200
PKC	SC-17769	Santa Cruz Biotechnology, Inc.	Monoclonal	1:250
Panx1	ACC-234	Alomone Labs,	Polyclonal	1:100
P2Y2R	APR-010	Alomone Labs,	Polyclonal	1:250
CD-31	RM5201	Invitrogen, Carlsbad, Ca, USA	Monoclonal	1:100

Plasmid generation and transfection into HEK293 cells.

The TRPV4 coding sequence without stop codons was amplified from mouse heart cDNA. The amplified fragment was inserted into a plasmid backbone containing a CMV promoter region for

expression and in addition, is suitable for lentiviral production by Gibson assembly. The in-frame FLAG tag was inserted into the 3'-primer used for amplification. Constructs were verified by sequencing the regions that had been inserted into the plasmid backbone. HEK293 cells were seeded (7×10^5 cells per 100 mm dish) in Dulbecco's Modified Eagle Medium with 10% fetal bovine serum (Thermo Fisher Scientific Inc., Waltham, MA, USA) 1 day prior to transfection. Cells were transfected using the LipofectamineLTX protocol (Thermo Fisher Scientific Inc., Waltham, MA, USA). TRPV4 was co-expressed with PKC α and PKC β , obtained from Origene Technologies (Montgomery County, MD).

Patch clamp in HEK293 cells and freshly isolated ECs.

TRPV4 channel current was recorded in HEK293 cells using whole-cell patch configuration 48 hrs after transfection. The intracellular solution consisted of (in mmol/L) 20 CsCl, 100 Cs-aspartate, 1 MgCl₂, 4 ATP, 0.08 CaCl₂, 10 BAPTA, 10 HEPES, pH 7.2 (adjusted with CsOH). Currents were measured using a voltage clamp protocol where voltage-ramp pulses (-100 mV to +100 mV) were applied over 200 ms with a holding potential of -50 mV. TRPV4 currents were measured before or 5 minutes after treatment. The extracellular solution consisted of (in mmol/L) 10 HEPES, 134 NaCl, 6 KCl, 2 CaCl₂, 10 glucose, and 1 MgCl₂ (adjusted to pH 7.4 with NaOH). Narishige PC-100 puller (Narishige International USA, INC., Amityville, NY, USA) was utilized to pull patch electrodes using borosilicate glass (O.D.: 1.5 mm; I.D.: 1.17 mm; Sutter Instruments, Novato, CA, USA). Patch electrodes were polished using MicroForge MF-830 polisher (Narishige International USA, INC., Amityville, NY, USA). The pipette resistance was (3–5 Ω M). Amphotericin B was dissolved in the intracellular pipette solution to reach a final concentration of 0.3 μ mol/L. Data were acquired using HEKA EPC 10 amplifier and PatchMaster

v2X90 program (Harvard Bioscience, Holliston, MA, USA), and analyzed using FitMaster v2X73.2 (Harvard Bioscience, Holliston, MA, USA) and MATLAB R2018a (MathWorks, Natick, MA, USA).

Fresh ECs were obtained via enzymatic digestion of 4th-order PAs. Briefly, PAs were incubated in the dissociation solution (in mmol/L, 55 NaCl, 80 Na glutamate, 6 KCl, 2 MgCl₂, 0.1 CaCl₂, 10 glucose, 10 HEPES, pH 7.3) containing Worthington neutral protease (0.5 mg/mL) for 30 minutes at 37°C. The extracellular solution consisted of (in mmol/L) 10 HEPES, 134 NaCl, 6 KCl, 2 CaCl₂, 10 glucose, and 1 MgCl₂ (adjusted to pH 7.4 with NaOH). The intracellular pipette solution for perforated-patch configuration consisted of (in mmol/L) 10 HEPES, 30 KCl, 10 NaCl, 110 K-aspartate, and 1 MgCl₂ (adjusted to pH 7.2 with NaOH). Cells were kept at room temperature in a bathing solution consisting of (in mmol/L) 10 HEPES, 134 NaCl, 6 KCl, 2 CaCl₂, 10 glucose, and 1 MgCl₂ (adjusted to pH 7.4 with NaOH). TRPV4 channel current was recorded from freshly isolated ECs as described previously^{25, 61}. Briefly, GSK101-induced outward currents through TRPV4 channels were assessed in response to a 200-ms voltage step from -45 mV to +100 mV in the presence of ruthenium red in order to prevent Ca²⁺ and activation of IK/SK channels at negative voltages. Outward currents were obtained by averaging the currents through the voltage step. GSK219-sensitive currents were obtained by subtracting the currents in the presence of GSK219 from the currents in the presence of GSK101.

Statistical analysis.

Results are presented as mean ± SEM. The n=1 was defined as one artery in the imaging experiments (Ca²⁺ imaging, PLA), one cell for patch clamp experiments, one mouse for RVSP

measurements, one artery for pressure myography experiments, one mouse for functional MRI, one mouse for ATP measurements, and one mouse for qPCR experiments. The data were obtained from at least five mice in experiments performed in at least two independent batches. The individual data points are shown each dataset. For *in vivo* experiments, an independent team member performed random assignment of animals to groups and did not have knowledge of treatment assignment groups. All the *in vivo* experiments were blinded; information about the groups or treatments was withheld from the experimenter or from the team member who analyzed the data.

All data are shown in graphical form using CorelDraw Graphics Suite X7 (Ottawa, ON, Canada) and statistically analyzed using GraphPad Prism 8.3.0 (Sand Diego, CA). A power analysis to determine group sizes and study power (>0.8) was performed using GLIMMPSE software ($\alpha = 0.05$; $>20\%$ change). Using this method, we estimated at least 5 cells per group for patch clamp experiments, 5 arteries per group for imaging and pressure myography experiments, and 4 mice per group for RVSP measurements and MRI. A Shapiro-Wilk test was performed to determine normality. The data in this article were normally distributed; therefore, parametric statistics were performed. Data were analyzed using two-tailed, paired or independent t-test (for comparison of data collected from two different treatments), one-way ANOVA or two-way ANOVA (to investigate statistical differences among more than two different treatments). Tukey correction was performed for multiple comparisons with one-way ANOVA, and Bonferroni correction was performed for multiple comparisons with two-way ANOVA. Statistical significance was determined as a P value less than 0.05.

Acknowledgements

The mouse strain *cdh5-optoα1AR* was developed by CHROMusTM which is supported by the National Heart Lung Blood Institute of the National Institute of Health under award number R24HL120847.

Sources of Funding

This work was supported by grants from the National Institutes of Health to SKS (R01HL142808, R01HL146914) and to VEL/SKS (R01HL157407).

Disclosures

The authors have no conflicts to disclose.

References

1. Navis KE, Fan CY, Trang T, Thompson RJ and Derksen DJ. Pannexin 1 Channels as a Therapeutic Target: Structure, Inhibition, and Outlook. *ACS Chem Neurosci*. 2020;11:2163-2172.
2. Begandt D, Good ME, Keller AS, DeLalio LJ, Rowley C, Isakson BE and Figueroa XF. Pannexin channel and connexin hemichannel expression in vascular function and inflammation. *BMC Cell Biol*. 2017;18:2.
3. Good ME, Begandt D, DeLalio LJ, Keller AS, Billaud M and Isakson BE. Emerging concepts regarding pannexin 1 in the vasculature. *Biochem Soc Trans*. 2015;43:495-501.
4. Bao L, Locovei S and Dahl G. Pannexin membrane channels are mechanosensitive conduits for ATP. *FEBS Lett*. 2004;572:65-8.
5. Lohman AW, Billaud M and Isakson BE. Mechanisms of ATP release and signalling in the blood vessel wall. *Cardiovasc Res*. 2012;95:269-80.
6. Gaynullina D, Shestopalov VI, Panchin Y and Tarasova OS. Pannexin 1 facilitates arterial relaxation via an endothelium-derived hyperpolarization mechanism. *FEBS Lett*. 2015;589:1164-70.
7. Gaynullina D, Tarasova OS, Kiryukhina OO, Shestopalov VI and Panchin Y. Endothelial function is impaired in conduit arteries of pannexin1 knockout mice. *Biol Direct*. 2014;9:8.

- 599 8. Sharma AK, Charles EJ, Zhao Y, Narahari AK, Baderdinni PK, Good ME, Lorenz UM, Kron IL, Bayliss
600 DA, Ravichandran KS, Isakson BE and Laubach VE. Pannexin-1 channels on endothelial cells mediate
601 vascular inflammation during lung ischemia-reperfusion injury. *Am J Physiol Lung Cell Mol Physiol*.
602 2018;315:L301-L312.
- 603 9. Marziano C, Hong K, Cope EL, Kotlikoff MI, Isakson BE and Sonkusare SK. Nitric Oxide-Dependent
604 Feedback Loop Regulates Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Cooperativity and
605 Endothelial Function in Small Pulmonary Arteries. *J Am Heart Assoc*. 2017;6.
- 606 10. Lyubchenko T, Woodward H, Veo KD, Burns N, Nijmeh H, Liubchenko GA, Stenmark KR and
607 Gerasimovskaya EV. P2Y1 and P2Y13 purinergic receptors mediate Ca²⁺ signaling and proliferative
608 responses in pulmonary artery vasa vasorum endothelial cells. *Am J Physiol Cell Physiol*. 2011;300:C266-
609 75.
- 610 11. McMillan MR, Burnstock G and Haworth SG. Vasodilatation of intrapulmonary arteries to P2-
611 receptor nucleotides in normal and pulmonary hypertensive newborn piglets. *Br J Pharmacol*.
612 1999;128:543-8.
- 613 12. Yamamoto K, Sokabe T, Ohura N, Nakatsuka H, Kamiya A and Ando J. Endogenously released ATP
614 mediates shear stress-induced Ca²⁺ influx into pulmonary artery endothelial cells. *Am J Physiol Heart Circ*
615 *Physiol*. 2003;285:H793-803.
- 616 13. Konduri GG and Mital S. Adenosine and ATP cause nitric oxide-dependent pulmonary vasodilation
617 in fetal lambs. *Biol Neonate*. 2000;78:220-9.
- 618 14. Mamenko M, Zaika O, Jin M, O'Neil RG and Pochynyuk O. Purinergic activation of Ca²⁺-permeable
619 TRPV4 channels is essential for mechano-sensitivity in the aldosterone-sensitive distal nephron. *PLoS One*.
620 2011;6:e22824.
- 621 15. Lorenzo IM, Liedtke W, Sanderson MJ and Valverde MA. TRPV4 channel participates in receptor-
622 operated calcium entry and ciliary beat frequency regulation in mouse airway epithelial cells. *Proc Natl*
623 *Acad Sci U S A*. 2008;105:12611-6.
- 624 16. Bernatchez PN, Bauer PM, Yu J, Prendergast JS, He P and Sessa WC. Dissecting the molecular
625 control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. *Proc Natl Acad Sci U S A*.
626 2005;102:761-6.
- 627 17. Goedicke-Fritz S, Kaistha A, Kacik M, Markert S, Hofmeister A, Busch C, Banfer S, Jacob R, Grgic I
628 and Hoyer J. Evidence for functional and dynamic microcompartmentation of Cav-1/TRPV4/K(Ca) in
629 caveolae of endothelial cells. *Eur J Cell Biol*. 2015;94:391-400.
- 630 18. DeLalio LJ, Keller AS, Chen J, Boyce AKJ, Artamonov MV, Askew-Page HR, Keller TCSt, Johnstone
631 SR, Weaver RB, Good ME, Murphy SA, Best AK, Mintz EL, Penuela S, Greenwood IA, Machado RF, Somlyo
632 AV, Swayne LA, Minshall RD and Isakson BE. Interaction Between Pannexin 1 and Caveolin-1 in Smooth
633 Muscle Can Regulate Blood Pressure. *Arterioscler Thromb Vasc Biol*. 2018;38:2065-2078.
- 634 19. Martinez NA, Ayala AM, Martinez M, Martinez-Rivera FJ, Miranda JD and Silva WI. Caveolin-1
635 Regulates the P2Y2 Receptor Signaling in Human 1321N1 Astrocytoma Cells. *J Biol Chem*. 2016;291:12208-
636 22.
- 637 20. Bakhshi FR, Mao M, Shajahan AN, Piegeler T, Chen Z, Chernaya O, Sharma T, Elliott WM, Szulcek
638 R, Bogaard HJ, Comhair S, Erzurum S, van Nieuw Amerongen GP, Bonini MG and Minshall RD. Nitrosation-
639 dependent caveolin 1 phosphorylation, ubiquitination, and degradation and its association with idiopathic
640 pulmonary arterial hypertension. *Pulm Circ*. 2013;3:816-30.
- 641 21. Maniatis NA, Shinin V, Schraufnagel DE, Okada S, Vogel SM, Malik AB and Minshall RD. Increased
642 pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1-/- mice. *Am J Physiol*
643 *Lung Cell Mol Physiol*. 2008;294:L865-73.
- 644 22. Nickel NP, Spiekerkoetter E, Gu M, Li CG, Li H, Kaschwich M, Diebold I, Hennigs JK, Kim KY,
645 Miyagawa K, Wang L, Cao A, Sa S, Jiang X, Stockstill RW, Nicolls MR, Zamanian RT, Bland RD and

- Rabinovitch M. Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling. *Am J Respir Crit Care Med*. 2015;191:1273-86.
23. Ottolini M, Hong K, Cope EL, Daneva Z, DeLalio LJ, Sokolowski JD, Marziano C, Nguyen NY, Altschmied J, Haendeler J, Johnstone SR, Kalani MY, Park MS, Patel RP, Liedtke W, Isakson BE and Sonkusare SK. Local Peroxynitrite Impairs Endothelial TRPV4 Channels and Elevates Blood Pressure in Obesity. *Circulation*. 2020.
24. Poon IK, Chiu YH, Armstrong AJ, Kinchen JM, Juncadella IJ, Bayliss DA and Ravichandran KS. Unexpected link between an antibiotic, pannexin channels and apoptosis. *Nature*. 2014;507:329-34.
25. Sonkusare SK, Bonev AD, Ledoux J, Liedtke W, Kotlikoff MI, Heppner TJ, Hill-Eubanks DC and Nelson MT. Elementary Ca²⁺ signals through endothelial TRPV4 channels regulate vascular function. *Science*. 2012;336:597-601.
26. Konduri GG, Bakhutashvili I, Frenn R, Chandrasekhar I, Jacobs ER and Khanna AK. P2Y purine receptor responses and expression in the pulmonary circulation of juvenile rabbits. *Am J Physiol Heart Circ Physiol*. 2004;287:H157-64.
27. Syed NI, Tengah A, Paul A and Kennedy C. Characterisation of P2X receptors expressed in rat pulmonary arteries. *European journal of pharmacology*. 2010;649:342-8.
28. Hennigs JK, Luneburg N, Stage A, Schmitz M, Korbelen J, Harbaum L, Matuszcak C, Mienert J, Bokemeyer C, Boger RH, Kieffmann R and Klose H. The P2-receptor-mediated Ca(2+) signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension. *Purinergic Signal*. 2019;15:299-311.
29. Zemskov E, Lucas R, Verin AD and Umapathy NS. P2Y receptors as regulators of lung endothelial barrier integrity. *Journal of cardiovascular disease research*. 2011;2:14-22.
30. Hu G, Vogel SM, Schwartz DE, Malik AB and Minshall RD. Intercellular adhesion molecule-1-dependent neutrophil adhesion to endothelial cells induces caveolae-mediated pulmonary vascular hyperpermeability. *Circ Res*. 2008;102:e120-31.
31. Saliez J, Bouzin C, Rath G, Ghisdal P, Desjardins F, Rezzani R, Rodella LF, Vriens J, Nilius B, Feron O, Balligand JL and Dessy C. Role of caveolar compartmentation in endothelium-derived hyperpolarizing factor-mediated relaxation: Ca²⁺ signals and gap junction function are regulated by caveolin in endothelial cells. *Circulation*. 2008;117:1065-74.
32. Fan HC, Zhang X and McNaughton PA. Activation of the TRPV4 ion channel is enhanced by phosphorylation. *J Biol Chem*. 2009;284:27884-91.
33. Airan RD, Thompson KR, Fenno LE, Bernstein H and Deisseroth K. Temporally precise in vivo control of intracellular signalling. *Nature*. 2009;458:1025-9.
34. Mineo C, Ying YS, Chapline C, Jaken S and Anderson RG. Targeting of protein kinase Calpha to caveolae. *The Journal of cell biology*. 1998;141:601-10.
35. Martin E, Dahan D, Cardouat G, Gillibert-Duplantier J, Marthan R, Savineau JP and Ducret T. Involvement of TRPV1 and TRPV4 channels in migration of rat pulmonary arterial smooth muscle cells. *Pflugers Arch*. 2012;464:261-72.
36. Ottolini M, Daneva Z, Chen YL, Cope EL, Kasetti RB, Zode GS and Sonkusare SK. Mechanisms underlying selective coupling of endothelial Ca(2+) signals with eNOS vs. IK/SK channels in systemic and pulmonary arteries. *J Physiol*. 2020.
37. Yang XR, Lin MJ, McIntosh LS and Sham JS. Functional expression of transient receptor potential melastatin- and vanilloid-related channels in pulmonary arterial and aortic smooth muscle. *Am J Physiol Lung Cell Mol Physiol*. 2006;290:L1267-76.
38. Xia Y, Fu Z, Hu J, Huang C, Paudel O, Cai S, Liedtke W and Sham JS. TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension. *Am J Physiol Cell Physiol*. 2013;305:C704-15.

39. Yang XR, Lin AH, Hughes JM, Flavahan NA, Cao YN, Liedtke W and Sham JS. Upregulation of osmo-mechanosensitive TRPV4 channel facilitates chronic hypoxia-induced myogenic tone and pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol*. 2012;302:L555-68.
40. Baxter M, Eltom S, Dekkak B, Yew-Booth L, Dubuis ED, Maher SA, Belvisi MG and Birrell MA. Role of transient receptor potential and pannexin channels in cigarette smoke-triggered ATP release in the lung. *Thorax*. 2014;69:1080-9.
41. Rahman M, Sun R, Mukherjee S, Nilius B and Janssen LJ. TRPV4 Stimulation Releases ATP via Pannexin Channels in Human Pulmonary Fibroblasts. *Am J Respir Cell Mol Biol*. 2018;59:87-95.
42. Locovei S, Wang J and Dahl G. Activation of pannexin 1 channels by ATP through P2Y receptors and by cytoplasmic calcium. *FEBS Lett*. 2006;580:239-44.
43. Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, Costell M, Maniscalco-Hauk K, Krawiec JA, Olzinski A, Gordon E, Lozinskaya I, Elefante L, Qin P, Matasic DS, James C, Tunstead J, Donovan B, Kallal L, Waszkiewicz A, Vaidya K, Davenport EA, Larkin J, Burgert M, Casillas LN, Marquis RW, Ye G, Eidam HS, Goodman KB, Toomey JR, Roethke TJ, Jucker BM, Schnackenberg CG, Townsley MI, Lepore JJ and Willette RN. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. *Science translational medicine*. 2012;4:159ra148.
44. Yin J, Hoffmann J, Kaestle SM, Neye N, Wang L, Baeurle J, Liedtke W, Wu S, Kuppe H, Pries AR and Kuebler WM. Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4. *Circ Res*. 2008;102:966-74.
45. Alvarez DF, King JA, Weber D, Addison E, Liedtke W and Townsley MI. Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. *Circ Res*. 2006;99:988-95.
46. Longden TA, Dabertrand F, Koide M, Gonzales AL, Tykocki NR, Brayden JE, Hill-Eubanks D and Nelson MT. Capillary K(+)-sensing initiates retrograde hyperpolarization to increase local cerebral blood flow. *Nat Neurosci*. 2017;20:717-726.
47. Kylhammar D, Bune LT and Radegran G. P2Y(1) and P2Y(1)(2) receptors in hypoxia- and adenosine diphosphate-induced pulmonary vasoconstriction in vivo in the pig. *Eur J Appl Physiol*. 2014;114:1995-2006.
48. Li Y, Hu H and O'Neil RG. Caveolae facilitate TRPV4-mediated Ca(2+) signaling and the hierarchical activation of Ca(2+)-activated K(+) channels in K(+)-secreting renal collecting duct cells. *Am J Physiol Renal Physiol*. 2018;315:F1626-F1636.
49. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J, Jr. and Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. *Proc Natl Acad Sci U S A*. 2002;99:11375-80.
50. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, Brovkovich V, Yuan JX, Wharton J and Malik AB. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. *J Clin Invest*. 2009;119:2009-18.
51. Mercado J, Baylie R, Navedo MF, Yuan C, Scott JD, Nelson MT, Brayden JE and Santana LF. Local control of TRPV4 channels by AKAP150-targeted PKC in arterial smooth muscle. *J Gen Physiol*. 2014;143:559-75.
52. Sonkusare SK, Dalsgaard T, Bonev AD, Hill-Eubanks DC, Kotlikoff MI, Scott JD, Santana LF and Nelson MT. AKAP150-dependent cooperative TRPV4 channel gating is central to endothelium-dependent vasodilation and is disrupted in hypertension. *Sci Signal*. 2014;7:ra66.
53. Moore C, Cevikbas F, Pasolli HA, Chen Y, Kong W, Kempkes C, Parekh P, Lee SH, Kontchou NA, Yeh I, Jokerst NM, Fuchs E, Steinhoff M and Liedtke WB. UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling. *Proc Natl Acad Sci U S A*. 2013;110:E3225-34.

54. Lohman AW, Leskov IL, Butcher JT, Johnstone SR, Stokes TA, Begandt D, DeLalio LJ, Best AK, Penuela S, Leitingner N, Ravichandran KS, Stokes KY and Isakson BE. Pannexin 1 channels regulate leukocyte emigration through the venous endothelium during acute inflammation. *Nature communications*. 2015;6:7965.
55. Billaud M, Chiu YH, Lohman AW, Parpaite T, Butcher JT, Mutchler SM, DeLalio LJ, Artamonov MV, Sandilos JK, Best AK, Somlyo AV, Thompson RJ, Le TH, Ravichandran KS, Bayliss DA and Isakson BE. A molecular signature in the pannexin1 intracellular loop confers channel activation by the alpha1 adrenoreceptor in smooth muscle cells. *Sci Signal*. 2015;8:ra17.
56. Chen Z, Bakhshi FR, Shajahan AN, Sharma T, Mao M, Trane A, Bernatchez P, van Nieuw Amerongen GP, Bonini MG, Skidgel RA, Malik AB and Minshall RD. Nitric oxide-dependent Src activation and resultant caveolin-1 phosphorylation promote eNOS/caveolin-1 binding and eNOS inhibition. *Mol Biol Cell*. 2012;23:1388-98.
57. Chen X, Qian S, Hoggatt A, Tang H, Hacker TA, Obukhov AG, Herring PB and Seye CI. Endothelial Cell-Specific Deletion of P2Y2 Receptor Promotes Plaque Stability in Atherosclerosis-Susceptible ApoE-Null Mice. *Arterioscler Thromb Vasc Biol*. 2017;37:75-83.
58. Wirth A, Benyo Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Orsy P, Horvath B, Maser-Gluth C, Greiner E, Lemmer B, Schutz G, Gutkind JS and Offermanns S. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. *Nat Med*. 2008;14:64-8.
59. Yang Y, DeLalio LJ, Best AK, Macal E, Milstein J, Donnelly I, Miller AM, McBride M, Shu X, Koval M, Isakson BE and Johnstone SR. Endothelial Pannexin 1 Channels Control Inflammation by Regulating Intracellular Calcium. *J Immunol*. 2020;204:2995-3007.
60. Vandsburger MH, French BA, Helm PA, Roy RJ, Kramer CM, Young AA and Epstein FH. Multi-parameter in vivo cardiac magnetic resonance imaging demonstrates normal perfusion reserve despite severely attenuated beta-adrenergic functional response in neuronal nitric oxide synthase knockout mice. *Eur Heart J*. 2007;28:2792-8.
61. Ottolini M, Hong K, Cope EL, Daneva Z, DeLalio LJ, Sokolowski JD, Marziano C, Nguyen NY, Altschmied J, Haendeler J, Johnstone SR, Kalani MY, Park MS, Patel RP, Liedtke W, Isakson BE and Sonkusare SK. Local Peroxynitrite Impairs Endothelial Transient Receptor Potential Vanilloid 4 Channels and Elevates Blood Pressure in Obesity. *Circulation*. 2020;141:1318-1333.

Figures.

Figure 1. Panx1_{EC}–TRPV4_{EC} signaling reduces PA contractility and lowers PAP. **A**, *top*, Immunofluorescence images of *en face* 4th-order PAs from TRPV4^{fl/fl} (*left*) and TRPV4^{EC-/-} (*right*) mice. CD31 immunofluorescence indicates endothelial cells. *Bottom*, Average resting RVSP

values in TRPV4^{fl/fl}, TRPV4^{EC-/-}, and TRPV4^{SMC-/-} mice (n = 6; **P* < 0.05 vs. TRPV4^{fl/fl}; one-way ANOVA). **B**, *top*, Representative diameter traces showing ATP (1 μmol/L)-induced dilation of PAs from TRPV4^{fl/fl} and TRPV4^{EC-/-} mice, pre-constricted with the thromboxane A2 receptor analog U46619 (50 nmol/L). Fourth-order PAs were pressurized to 15 mm Hg. *Bottom*, Percent dilation of PAs from TRPV4^{fl/fl} and TRPV4^{EC-/-} mice in response to ATP (1 μmol/L; n = 5–10; ****P* < 0.01 vs. TRPV4^{fl/fl} [ATP 1 μmol/L]; t-test). **C**, *top*, Immunofluorescence images of *en face* 4th-order PAs from Panx1^{fl/fl} (*left*) and Panx1^{EC-/-} (*right*) mice. *Bottom*, Average resting RVSP values in Panx1^{fl/fl}, Panx1^{EC-/-} and Panx1^{SMC-/-} mice (n = 5; ***P* < 0.01 vs. Panx1^{fl/fl}; one-way ANOVA). **D**, *left*, Grayscale image of a field of view of an *en face* preparation of Fluo-4-loaded PAs from Panx1^{fl/fl} and Panx1^{EC-/-} mice showing approximately 20 ECs. Dotted areas indicate TRPV4^{EC} sparklet sites (20 μmol/L CPA + 10 nmol/L GSK101). *Center*, Representative traces showing TRPV4^{EC} sparklet activity in *en face* preparations of PAs from Panx1^{fl/fl} and Panx1^{EC-/-} mice in response to GSK101 (10 nmol/L). Experiments were performed in Fluo-4-loaded PAs in the presence of CPA (20 μmol/L), included to eliminate Ca²⁺ release from intracellular stores. *Right*, TRPV4^{EC} sparklet activity (NP_O) per site in *en face* preparations of PAs from Panx1^{fl/fl} and Panx1^{EC-/-} mice under baseline conditions (i.e., 20 μmol/L CPA) and in response to 1 nmol/L GSK101 (n = 6; **P* < 0.05, ***P* < 0.01 vs. Panx1^{fl/fl}; two-way ANOVA). ‘N’ is the number of channels per site and ‘P_O’ is the open state probability of the channel. **E**, TRPV4^{EC} sparklet activity, expressed as sites per cell, in *en face* preparations of PAs from Panx1^{fl/fl} and Panx1^{EC-/-} mice under baseline conditions (i.e., 20 μmol/L CPA) and in response to 1 nmol/L GSK101 (n = 6; **P* < 0.05 vs. Panx1^{fl/fl}; two-way ANOVA). **F**, TRPV4^{EC} sparklet activity (NP_O) per site and TRPV4 sparklet sites per cell in *en face* preparations of PAs from Panx1^{fl/fl} and Panx1^{EC-/-} mice in response to 30 nmol/L GSK101 (n = 6). **G**, *left*, representative GSK101 (10 nmol/L)-induced

outward TRPV_{4EC} currents in freshly isolated ECs from Panx1^{fl/fl} or Panx1^{EC-/-} mice and effect of GSK2193874 (GSK219, TRPV4 inhibitor, 100 nmol/L) in the presence of GSK101, currents were elicited by a 200 ms voltage step from -50 mV to +100 mV; *center*, scatterplot showing outward currents at +100 mV under baseline conditions, after the addition of GSK101 (10 nM), and after the addition of GSK219 (100 nM), n=5-6 cell, one-way ANOVA, *right*, scatterplot showing GSK219-sensitive TRPV_{4EC} currents in the presence of GSK101 (100 nmol/L; n = 5). **H**, *top*, an image showing the left lung and the order system used to isolate 4th order PAs in this study; *bottom*, an image of a 4th order PA cannulated and pressurized at 15 mm Hg. **I**, *left*, Percent constriction of PAs from TRPV4^{fl/fl} and TRPV4^{EC-/-} mice in response to U46619 (1–300 nmol/L) (n = 5; *P < 0.05, **P < 0.01 vs. Panx1^{fl/fl}; two-way ANOVA). *Right*, Percent constriction of PAs from Panx1^{fl/fl} and Panx1^{EC-/-} mice in response to U46619 (1–300 nmol/L; n = 5; ***P < 0.001 vs. Panx1^{fl/fl}; two-way ANOVA).

Table 1. Fulton Index and Functional MRI analysis of cardiac function in TRPV4^{fl/fl}, TRPV4^{EC-/-}, Panx1^{fl/fl} and Panx1^{EC-/-} mice. Average Fulton Index, end diastolic and systolic volume (EDV and ESV; μ L), ejection fraction (EF; %), stroke volume (SV; μ L), R-R interval (ms), and cardiac output (CO; mL/min). Data are presented as means $\pm$ SEM (n = 5–8 mice).

	TRPV4^{fl/fl}	TRPV4^{EC-/-}	Panx1^{fl/fl}	Panx1^{EC-/-}
Fulton Index	0.22 $\pm$ 0.02	0.24 $\pm$ 0.01	0.23 $\pm$ 0.01	0.26 $\pm$ 0.03
EDV (μL)	51.4 $\pm$ 5.6	57.4 $\pm$ 6.5	46.9 $\pm$ 2.7	50.9 $\pm$ 2.9
ESV (μL)	21.5 $\pm$ 3.5	25.1 $\pm$ 4.9	14.8 $\pm$ 1.7	13.1 $\pm$ 1.4
EF (%)	58.9 $\pm$ 2.7	57.4 $\pm$ 3.3	68.9 $\pm$ 2.0	74.3 $\pm$ 2.3
SV (μL)	29.9 $\pm$ 2.4	32.3 $\pm$ 1.9	32.2 $\pm$ 1.3	37.8 $\pm$ 2.4
R-R (ms)	124.3 $\pm$ 6.0	125.6 $\pm$ 6.7	127.1 $\pm$ 5.5	130.8 $\pm$ 2.5
CO (mL/min)	14.6 $\pm$ 1.3	15.5 $\pm$ 1.0	15.2 $\pm$ 0.6	17.3 $\pm$ 1.2

Figure 2. eATP activates TRPV4_{EC} channels via P2Y2_{REC} stimulation. **A**, Release of ATP (nmol/L) from PAs of Panx1^{fl/fl}, Panx1^{EC-/-}, TRPV4^{fl/fl}, and TRPV4^{EC-/-} mice (n = 5–6; *P < 0.05 vs. Panx1^{fl/fl}; t-test]. **B**, *left*, Representative traces showing TRPV4_{EC} sparklet activity in *en face* preparations of PAs from Panx1^{fl/fl} mice in the absence or presence of apyrase (10 U/mL). Experiments were performed in Fluo-4–loaded PAs in the presence of CPA (20 μmol/L), included to eliminate Ca²⁺ release from intracellular stores. *Right*, TRPV4_{EC} sparklet activity (NP₀) per site in *en face* preparations of PAs from Panx1^{fl/fl} and Panx1^{EC-/-} mice in the presence or absence of

849 apyrase (10 U/mL; n = 5; *** $P < 0.001$ vs. $Panx1^{fl/fl}$ [-apyrase, 10 U/mL]; one-way ANOVA). **C**,
850 *left*, Immunofluorescence images of *en face* 4th-order PAs from $P2Y2R^{fl/fl}$ and $P2Y2R_{EC}^{-/-}$ mice.
851 *Right*, Effects of ATP (10 μ mol/L) on TRPV4_{EC} sparklet activity in the absence or presence of the
852 P2Y1R inhibitor MRS2179 (MRS; 10 μ mol/L) or P2Y2R inhibitor AR-C 118925XX (ARC; 10
853 μ mol/L) in PAs from $P2Y2R^{fl/fl}$ mice and $P2Y2R_{EC}^{-/-}$ mice, expressed as NP_O per site (n = 5; *** P
854 < 0.001 , ** $P < 0.01$ vs. -ATP; one-way ANOVA). **D**, Effects of ATP (10 μ mol/L) on TRPV4_{EC}
855 sparklet activity in the presence of the general P2X1-5/7R inhibitor PPADS (10 μ mol/L) and
856 P2X7R inhibitor JNJ-47965567 (JNJ; 1 μ mol/L) in PAs of C57BL6/J mice (n = 5; * $P < 0.05$ vs.
857 [-ATP, 10 μ mol/L]; one-way ANOVA). **E**, *top*, representative ATP (10 μ mol/L)-induced outward
858 TRPV4 currents in freshly isolated ECs from C57BL6 mice and effect of GSK2193874 (GSK219,
859 TRPV4 inhibitor, 100 nmol/L) in the presence of ATP, currents were elicited by a 200 ms voltage
860 step from -50 mV to +100 mV; *bottom*, scatterplot showing outward currents at +100 mV under
861 baseline conditions, after the addition of ATP, and after the addition of GSK219 (100 nM), n=6
862 cells, one-way ANOVA. **F**, *left*, Representative traces showing TRPV4_{EC} sparklet activity in *en*
863 *face* preparations of PAs from $P2Y2R^{fl/fl}$ mice in response to CPA (20 μ mol/L) + GSK101 (1
864 nmol/L), CPA + 2-thio UTP (0.5 μ mol/L), or CPA + GSK219 (100 nmol/L). *Right*, TRPV4_{EC}
865 sparklet activity (NP_O) per site in *en face* preparations of PAs from $P2Y2R^{fl/fl}$ and $P2Y2R_{EC}^{-/-}$ mice
866 under baseline conditions (i.e., 20 μ mol/L CPA) and in response to 2-thio UTP (0.5 μ mol/L; n =
867 5; * $P < 0.05$ vs. $P2Y2R^{fl/fl}$ [-2-thio UTP]; two-way ANOVA). **G**, *left*, Average resting RVSP
868 values in $P2Y2R^{fl/fl}$ and $P2Y2R_{EC}^{-/-}$ mice (n = 6, * $P < 0.05$). *Right*, Average Fulton Index values
869 in $P2Y2R^{fl/fl}$ and $P2Y2R_{EC}^{-/-}$ mice (n = 5–6).

870

871

Figure 3. Cav-1_{EC} provides a signaling scaffold for Panx1_{EC}–P2Y2_{REC}–TRPV4_{EC} signaling

in PAs. **A**, Immunofluorescence images of *en face* 4th-order PAs from Cav-1^{fl/fl} (top) and Cav-1^{EC-/-} (bottom) mice. **B**, Endothelial Cav-1 mRNA levels in PAs relative to those in Cav-1^{fl/fl} mice (n = 4; ****P* < 0.001; t-test). **C**, left, Average resting RVSP values in Cav-1^{fl/fl} and Cav-1^{EC-/-} mice (n = 6; **P* < 0.05 vs. Cav-1^{fl/fl}; one-way ANOVA). Right, Average Fulton Index values

in Cav-1^{fl/fl} and Cav-1^{EC-/-} mice (n = 5–6). **D**, TRPV4_{EC} sparklet activity (NP_O) per site in *en face* preparations of PAs from Cav-1^{fl/fl} and Cav-1^{EC-/-} mice at baseline and in response to 30 nmol/L GSK101 (n = 6; **P < 0.01 vs. baseline Cav-1^{fl/fl}; one-way ANOVA). Experiments were performed in Fluo-4–loaded 4th-order PAs in the presence of CPA (20 μmol/L), included to eliminate Ca²⁺ release from intracellular stores. **E**, *left*, Representative traces showing TRPV4_{EC} sparklets in *en face* preparations of PAs from Cav-1^{fl/fl} and Cav-1^{EC-/-} mice in the presence and absence of ATP (10 μmol/L). *Right*, TRPV4_{EC} sparklet activity (NP_O) per site in *en face* preparations of PAs from Cav-1^{fl/fl} and Cav-1^{EC-/-} mice in the presence or absence of 10 μmol/L ATP (n = 5; *P < 0.05; **P < 0.01 vs. [-ATP] Cav-1^{fl/fl}; two-way ANOVA). **F**, *top*, Representative merged images of proximity ligation assays (PLA) showing EC nuclei and Cav-1_{EC}:Panx1_{EC}, Cav-1_{EC}:P2Y2_{EC}, and Cav-1_{EC}:TRPV4_{EC} co-localization (white puncta) in 4th-order PAs from Cav-1^{fl/fl} and Cav-1^{EC-/-} mice. *Bottom*, Quantification of Cav-1_{EC}:Panx1_{EC}, Cav-1_{EC}:P2Y2_{EC}, and Cav-1_{EC}:TRPV4_{EC} co-localization in PAs from Cav-1^{fl/fl} and Cav-1^{EC-/-} mice (n = 5; *** P < 0.001 vs. Cav-1^{fl/fl}; t-test).

Figure 4. eATP activates TRPV4_{EC} channels via P2Y2_{EC}–PLC–PKC signaling in PAs. **A**, *left*, Representative traces showing TRPV4_{EC} sparklet activity in *en face* preparations of PAs from C57BL6/J mice before and after treatment with ATP (10 μ mol/L). *Right*, Effects of U73122 (PLC inhibitor; 3 μ mol/L) or G6-6976 (PKC α / β inhibitor; 1 μ mol/L) on TRPV4_{EC} sparklet activity in *en face* preparations of PAs from C57BL6/J mice before and after treatment with ATP (10 μ mol/L), expressed as NP₀ per site. Experiments were performed in Fluo-4–loaded 4th-order PAs

in the presence of CPA (20 $\mu\text{mol/L}$), included to eliminate Ca^{2+} release from intracellular stores ($n = 5$; $*P < 0.05$ vs. [-ATP]; one-way ANOVA). **B**, *left*, Representative traces showing TRPV4_{EC} sparklet activity in *en face* preparations of PAs from C57BL6/J mice in the absence or presence of OAG (DAG analogue; 1 $\mu\text{mol/L}$). *Right*, Effects of U73122 (3 $\mu\text{mol/L}$) or Gö-6976 (1 $\mu\text{mol/L}$) on TRPV4_{EC} sparklet activity in *en face* preparations of PAs from C57BL6/J mice before and after treatment with OAG (1 $\mu\text{mol/L}$), expressed as NP_O per site ($n = 6$; $**P < 0.01$ vs. [-OAG]; one-way ANOVA). **C**, *left*, Representative traces showing TRPV4_{EC} sparklets in *en face* preparations of PAs from C57BL6/J mice in the absence or presence of PMA (PKC activator; 10 nmol/L). *Right*, Effects of U73122 (3 $\mu\text{mol/L}$) or Gö-6976 (1 $\mu\text{mol/L}$) on TRPV4_{EC} sparklet activity in *en face* preparations of PAs from C57BL6/J mice before and after treatment with PMA (10 nmol/L), expressed as NP_O per site ($n = 6$; $*P < 0.05$ vs. [-PMA]; one-way ANOVA). **D**. *top*, Representative traces showing TRPV4_{EC} sparklet activity in *en face* preparations of PAs from Cdh5-opto α 1AR (adrenergic receptor) mouse before and after the light activation (470 nm); *bottom*, scatter plot showing the sparklet activity, expressed as sparklet sites per cell, before and after the light activation, in the absence or presence of PKC α/β inhibitor Gö-6976 (1 μM , $n=4$, $***P < 0.001$).

Figure 5. Localization of PKCα with Cav-1_{EC} increases the activity of TRPV4_{EC} channels. **A**, top, Representative merged images of proximity ligation assays (PLA) showing EC nuclei and Cav-1:PKC co-localization (white puncta) in 4th-order PAs from Cav-1^{fl/fl} and Cav-1^{EC-/-} mice. Bottom, Quantification of Cav-1:PKC co-localization in PAs from Cav-1^{fl/fl} and Cav-1^{EC-/-} mice (n = 5; ***P < 0.001 vs. Cav-1^{fl/fl}; t-test). **B**, Representative traces showing TRPV4 currents in the absence or presence of Gö-6976 (PKC inhibitor; 1 μmol/L) in HEK293 cells transfected with TRPV4 only or co-transfected with TRPV4 plus wild-type Cav-1, recorded in the whole-cell patch-clamp configuration. **C**, Current density plot of TRPV4 currents at +100 mV in the absence

or presence of Gö6976 (1 μ mol/L) in HEK293 cells transfected with TRPV4 or TRPV4 + Cav-1 (n = 5; ** P < 0.01 vs. Control; one-way ANOVA). **D**, Current density plot of TRPV4 currents at +100 mV in HEK293 cells transfected with TRPV4 + PKC α or TRPV4 + PKC β (n = 5; *** P < 0.001 vs. TRPV4 + PKC α ; t-test). **E**, Schematic depiction of the Panx1_{EC}–P2Y2_{EC}–TRPV4_{EC} signaling pathway that promotes vasodilation and lowers PAP in PAs. ATP released from Panx1_{EC} channels activates P2Y2_{EC} purinergic receptors on the EC membrane. Stimulation of P2Y2_{EC} recruits PKC α , which anchors to the scaffolding protein Cav-1_{EC} in close proximity to TRPV4_{EC} channels. TRPV4_{EC} channel-dependent vasodilation lowers pulmonary arterial pressure (PAP).